Radiopharm Theranostics Ltd has released a press release.
RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Story so far
- Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
- RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
- Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Quarterly Activities/Appendix 4C Cash Flow Report
- Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
Later from Radiopharm Theranostics
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
- Half Year Report and Appendix 4D 31 December 2025
- RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics